<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232023000100019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El péptido Pro-BNP como predictor de daño cardíaco en pacientes con esclerosis sistémica]]></article-title>
<article-title xml:lang="en"><![CDATA[Pro-BNP Peptide as a Predictor of Cardiac Damage in Systemic Sclerosis Patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chico Capote]]></surname>
<given-names><![CDATA[Araceli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estévez del Toro]]></surname>
<given-names><![CDATA[Miguel Hernán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro Arca]]></surname>
<given-names><![CDATA[Ángela María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gálvez Vallejo]]></surname>
<given-names><![CDATA[Juan Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Puente Carmona]]></surname>
<given-names><![CDATA[Rolando Dayan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Docente Clínico Quirúrgico &#8220;Hermanos Ameijeiras&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General Clínico-Quirúrgico &#8220;Monte Sinaí&#8221;  ]]></institution>
<addr-line><![CDATA[ Guayaquil]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<volume>62</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232023000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232023000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232023000100019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La esclerosis sistémica es una enfermedad crónica del tejido conectivo de carácter autoinmune, de causa desconocida, que produce exceso de colágeno provocando fibrosis en la piel, con afectación de órganos internos. Los anticuerpos frecuentes son: antitopoisomerasa 1 y anticentrómero. Las formas clínicas son la cutánea difusa y cutánea limitada. La prevalencia de la afectación cardíaca varía entre un 8-28 % y en fases tardías la presencia de signos y síntomas cardiovasculares es de mal pronóstico y una de las principales causas de mortalidad.  Objetivo:  Determinar la asociación entre afectación cardíaca y las formas clínicas, el pro-péptido natriurético cerebral N-terminal (NT-proBNP) y los autoanticuerpos en la esclerosis sistémica.  Métodos:  Se realizó un estudio descriptivo transversal de un universo de 140 pacientes, la muestra fue de 54 pacientes. Se le realizó ecocardiograma, niveles de NT-proBNP, anti-scl 70, anticentrómero y determinación de formas clínicas a todos los pacientes que cumplieron criterios de inclusión y que fueron atendidos en el Hospital: &#8220;Hermanos Ameijeiras&#8221; Habana-Cuba, entre julio de 2016 a diciembre de 2017.  Resultados:  La edad media fue 51,76 ± 12,82. Sexo femenino en un 96,3 %. El 72,2 % era piel blanca. La afectación cardíaca de la EScd fue de 77,5 %, hormona NT-proBNP tuvo niveles elevados en un 55,0 %. Los anti-scl-70 estuvieron negativos en el 70 % (n = 28) de los pacientes con afectación cardíaca. El anti-centrómero estuvo negativo en el 95,0 % (n = 38).  Conclusiones:  Se determinó que la afectación cardíaca en pacientes con esclerosis sistémica, es independiente de las formas clínicas y de la presencia de autoanticuerpos. Los pacientes que tuvieron los niveles séricos de NT-proBNP elevados presentaron afectación cardíaca.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Systemic sclerosis is a chronic autoimmune connective tissue disease of unknown cause, which produces excess collagen causing fibrosis in the skin, affecting internal organs. Common antibodies are antitopoisomerase 1 and anticentromere. The clinical forms are diffuse cutaneous and limited cutaneous. The prevalence of cardiac involvement varies between 8-28% and in late stages the presence of cardiovascular signs and symptoms have poor prognosis and one of the main causes of mortality.  Objective:  To determine the association between cardiac involvement and clinical forms, N-terminal pro-brain natriuretic peptide (NT-proBNP) and autoantibodies in SSc.  Methods: A cross-sectional descriptive study of a universe of 140 patients was carried out. Fifty four patients made up the sample. An echocardiogram, NT-proBNP, Anti-scl 70, anticentromere levels and determination of clinical forms were performed on all patients who met the inclusion criteria and who were treated at Hermanos Ameijeiras hospital in Havana, Cuba, from July 2016 to December 2017. Results: The mean age was 51.76 ± 12.82. Female sex accounted 96.3%. 72.2% were white skinned. Cardiac involvement of EScd was 77.5%, NT-proBNP hormone had high levels in 55.0%. Anti-scl-70 were negative in 70% (n=28) of patients with cardiac involvement. Anti-centromere (ACT) was negative in 95.0% (n=38).  Conclusions:  Cardiac involvement in patients with SS is independent of the clinical forms and the presence of autoantibodies. Patients with elevated NT-proBNP serum levels had cardiac involvement.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[NT-proBNP]]></kwd>
<kwd lng="es"><![CDATA[hipertensión pulmonar]]></kwd>
<kwd lng="es"><![CDATA[esclerosis sistémica]]></kwd>
<kwd lng="en"><![CDATA[NT-proBNP]]></kwd>
<kwd lng="en"><![CDATA[pulmonary hypertension]]></kwd>
<kwd lng="en"><![CDATA[systemic sclerosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perelas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silver]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Arrossi]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Highland]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic sclerosis-associated interstitial lung disease]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2020</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>304-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coffey]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Radwan]]></surname>
<given-names><![CDATA[YA]]></given-names>
</name>
<name>
<surname><![CDATA[Sandhu]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Crowson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Matteson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018) A Population-based Study]]></article-title>
<source><![CDATA[J Scleroderma Relat Disord]]></source>
<year>2021</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>264-70</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bairkdar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rossides]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Westerlind]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hesselstrand]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arkema]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Holmqvist]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and prevalence of systemic sclerosis globally a comprehensive systematic review and meta-analysis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2021</year>
<volume>60</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3121-33</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kudo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Umeda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Futakuchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sueyoshi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maemura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial Damage and Microvasculopathy in a Patient With Systemic Sclerosis]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2021</year>
<volume>85</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>224</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hosberg]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Davidica Mayes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Assassi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Conective Tissue disorders, Classification and Epidemiology of scleroderma]]></source>
<year>2015</year>
<volume>v</volume>
<numero>1</numero>
<edition>6ta</edition>
<issue>1</issue>
<page-range>1153-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diab]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dostrovsky]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tatibouet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fritzler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canadian Scleroderma Research Group Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2014</year>
<volume>41</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2179-85</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassaan]]></surname>
<given-names><![CDATA[M L]]></given-names>
</name>
</person-group>
<source><![CDATA[Consenso sobre esclerodermia]]></source>
<year>2015</year>
<page-range>1-30</page-range><publisher-name><![CDATA[Sociedad Argentina de Dermatología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina Yimy]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barrera]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chalem]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Motta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación de los experimentos anti-péptido citrulinado con manifestaciones osteoarticulares en una cohorte de pacientes con esclerodermia]]></article-title>
<source><![CDATA[Rev. Colomb. Reumatol]]></source>
<year>2011</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>155-62</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coghlan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac complications of systemic sclerosis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2009</year>
<volume>48</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>iii45-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bell Castillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[George Carrión]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[García Céspedes]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[George Bell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis sistémica progresiva en una mujer joven]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2015</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>628-37</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grosso]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Silver]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insuficiencia cardíaca]]></article-title>
<source><![CDATA[]]></source>
<year>2011</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>106-11</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foocharoen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pussadhamma]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mahakkanukrauh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suwannaroj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nanagara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asymptomatic cardiac involvement in Thai systemic sclerosis prevalence and clinical correlations with non-cardiac manifestations (preliminary report)]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2015</year>
<volume>54</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1616-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Champion]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The heart in scleroderma]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2008</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>181-90</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oram]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stokes]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The heart in scleroderma]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1961</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>243-59</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&amp;apos;Angelo]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Fries]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Masi]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Shulman]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathologic observations in systemic sclerosis (scleroderma) A study of fifty-eight autopsy cases and fifty-eight matched controls]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1969</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>428-40</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Respuesta clínica y ecocardiográfica en pacientes con hipertensión pulmonar y esclerosis sistémica tratados con sildenafil]]></source>
<year>2015</year>
<page-range>1-85</page-range><publisher-name><![CDATA[Universidad central de Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Byers]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[DAS]]></given-names>
</name>
<name>
<surname><![CDATA[Freemont]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Annals of the Rheumatic]]></article-title>
<collab>Pericardial involvement in systemic sclerosis</collab>
<source><![CDATA[Diseases]]></source>
<year>1997</year>
<volume>56</volume>
<page-range>393-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Satoh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tokuhira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hama]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hirakata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akizuki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Massive pericardial effusion in scleroderma a review of five cases]]></article-title>
<source><![CDATA[Br J Rheumatol]]></source>
<year>1995</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>564-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meune]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Allanore]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Devaux]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Dessault]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Duboc]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High prevalence of right ventricular systolic dysfunction in early systemic sclerosis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2004</year>
<volume>31</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1941-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobos Bejarano]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Horrillo García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González-González]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos Rodríguez]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Sánchez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos Maroto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validez y utilidad del péptido ventricular natriurético tipo B (BNP) en la detección de disfunción ventricular izquierda en pacientes de alto riesgo en atención primaria]]></article-title>
<source><![CDATA[Aten. Prim]]></source>
<year>2012</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García de la Peña Lefebvre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis sistémica y síndromes esclerodermiformes]]></article-title>
<source><![CDATA[Manual Ser de enfermedades reumáticas]]></source>
<year>2014</year>
<edition>6ta</edition>
<page-range>363-71</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Reumatología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Navarro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Jiménez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Otero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia Cubero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Almenar Bonet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Anguita Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad de los péptidos natriuréticos en la insuficiencia cardíaca]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2008</year>
<volume>130</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>591-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivero Soldevila]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Esclerosis sistémica: supervivencia y factores pronósticos]]></source>
<year>2013</year>
<page-range>2-102</page-range><publisher-name><![CDATA[Universidad Autónoma de Barcelona]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silveira-Torre]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afección cardíaca en la esclerosis sistémica]]></article-title>
<source><![CDATA[Reumatología Clinica]]></source>
<year>2006</year>
<volume>2</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>S531-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
